Hormonal
In postmenopausal women, higher levels of bioavailable testosterone are associated with an increased risk of incident type 2 diabetes, but this association is entirely mediated by adiposity (BMI) and insulin resistance.
For postmenopausal women, high testosterone levels are a warning sign of metabolic risk, but they are not the root cause. The risk comes from excess body fat and insulin resistance. Managing weight and insulin sensitivity is the primary way to mitigate this risk, rather than targeting testosterone levels directly.
After adjustment for body mass index and insulin resistance estimated by homeostasis model assessment of insulin resistance, bioavailable T was no longer associated with incident T2DM.
Why this rating
Prospective cohort study with large sample size (n=1612) and rigorous adjustment for confounders.
Source
The Association of Endogenous Sex Hormones, Adiposity, and Insulin Resistance with Incident Diabetes in Postmenopausal Women
Rita R. Kalyani et al. · The Journal of Clinical Endocrinology & Metabolism · 2009
DOI 10.1210/jc.2009-0910
More from this paper
- In postmenopausal women, higher levels of estradiol (E2) and lower levels of sex hormone-binding globulin (SHBG) are associated with an increased risk of incident type 2 diabetes, and these associations persist even after adjusting for adiposity and insulin resistance.Good
- Dehydroepiandrosterone (DHEA) levels are not associated with the risk of incident type 2 diabetes in postmenopausal women.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →